Airain Ltd’s GenMark Diagnostics, Inc GNMK Stock Holding History

Airain Ltd’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,394	Closed	-$159K	–	1114
2017 Q1	$159K	Buy	+12,394	New	+$149K	0.01%	736

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Airain Ltd's GNMK Position: Q2 2017 in Review

Airain Ltd sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2017, closing a stake of 12,394 shares — an estimated $159K sold.

Airain Ltd first reported a position in GNMK in Q1 2017 and held it in 1 quarter. The position peaked at $159K in Q1 2017. 99 funds tracked by Wall St. Rank hold GNMK as of Q2 2017.

Airain Ltd reported no remaining GenMark Diagnostics, Inc position as of Q2 2017 after selling out during the quarter.
Airain Ltd sold 12,394 GenMark Diagnostics, Inc shares in Q2 2017, an estimated $159K.
Airain Ltd first reported a position in GenMark Diagnostics, Inc in Q1 2017 and held it in 1 quarter.
Airain Ltd's GenMark Diagnostics, Inc position peaked at $159K in Q1 2017.
99 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.